Jazz Pharmaceuticals (JAZZ) Achieves New Milestone in JZP-110 Phase 3 for Excessive Sleepiness in Narcolepsy
Go back to Jazz Pharmaceuticals (JAZZ) Achieves New Milestone in JZP-110 Phase 3 for Excessive Sleepiness in Narcolepsy| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 108.07 -0.25 (0.23%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $108.32 | 52 Week High | $160.00 | |||
| Open | $108.25 | 52 Week Low | $95.80 | |||
| Day High | $109.05 | P/E | 20.09 | |||
| Day Low | $107.30 | EPS | $5.38 | |||
| Volume | 39,877 | |||||
